UNSPSC 51181565: Ponalrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C17H12BrFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2CV0A5G64E, chemically known as 3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid but generally known as ponalrestat, which bears US NIH Compound Identifier 5278. European Medicines Agency schedules Ponalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09978MIG.

UNSPSC 51181565 Ponalrestat is a Commodity code for a specific pharmaceutical active ingredient used in diabetes management; state and local governments procure it as part of formulary stocking and institutional pharmacy operations, typically through cooperative pharmaceutical purchasing agreements that bundle multiple generic and branded products under single contracts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits pharmaceuticals under this code through multi-vendor RFPs that establish baseline pricing and product availability across member jurisdictions spanning Minnesota, Oregon, and other participating states. The scope encompasses generic multi-source pharmaceuticals and OTC products distributed to state and local government health facilities, correctional institutions, and related agencies. Vendors must hold current Good Manufacturing Practice (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencara, Cardinal Health, Morris & Dickson), support electronic data interchange (EDI), and carry commercial general liability of $5 million per occurrence and professional liability of $2 million. Products must be FDA-compliant with expiration dates at least one year from manufacture and a minimum six-month shelf life.

MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026) is the primary recent opportunity visible under this code. The procurement weights price competitiveness at seventy-five percent of evaluation, with the remaining twenty-five percent distributed across fixed pricing (ten percent), EDI capability (five percent), administrative fee compliance (five percent), and format requirements (five percent). Awarded vendors pay a three percent administrative fee on all contract purchases and face performance penalties of $200 to $1,500 per violation for late reporting, missed timelines, or improper trade denials. The contract term runs two years for new vendors with optional MMCAP extensions, or through June 30, 2028 for incumbent amendments. No specific dollar budget, set-aside restrictions, or award quantities are disclosed in the solicitation materials.